Lemaitre Vascular Stock News

The Vascular Patches Market research report provides an in-depth assessment of the current and future industry prospects with detailed market insights and changing market scenarios. In addition, the research report offers strategic research methodologies that help readers to make robust

Navellier & Associates Inc. bought a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the third quarter, Holdings Channel.com reports. The institutional investor bought 10,019 shares of the medical instruments suppliers stock, valued at approximately $532,000. Other large investors have also modified their holdings of the company. Harbor Investment Advisory LLC purchased a new stake []

LeMaitre Vascular (NASDAQ:LMAT) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations. Profitability This table compares LeMaitre Vascular and Nephros net margins, return on equity and return on []

Wells Fargo & Company MN decreased its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 12.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 84,787 shares of the medical instruments suppliers stock after selling 12,064 shares during the period. Wells Fargo & Company MN []

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received an average recommendation of Hold from the six brokerages that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among []

Assenagon Asset Management S.A. acquired a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 72,234 shares of the medical instruments suppliers stock, valued at approximately $3,835,000. Other institutional investors have also recently added to or reduced their stakes in the company. Amundi purchased a []

Brokerages expect LeMaitre Vascular, Inc. (NASDAQ:LMAT) to post $39.99 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for LeMaitre Vasculars earnings. The highest sales estimate is $40.10 million and the lowest is $39.63 million. LeMaitre Vascular reported sales of $37.55 million in the same quarter last []

LeMaitre Vascular is a small-cap medical devices maker with the potential to continue growing rapidly in the years ahead.

LeMaitre Vascular is a small-cap medical devices maker with the potential to continue growing rapidly in the years ahead.

Squarepoint Ops LLC lessened its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 50.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,353 shares of the medical instruments suppliers stock after selling 6,350 shares during the quarter. Squarepoint Ops LLCs []

Charles Schwab Investment Management Inc. raised its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 24.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 141,906 shares of the medical instruments suppliers stock after acquiring an additional 27,912 shares during the []

Royal Bank of Canada raised its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 7.9% during the second quarter, HoldingsChannel reports. The firm owned 77,987 shares of the medical instruments suppliers stock after buying an additional 5,711 shares during the period. Royal Bank of Canadas holdings in LeMaitre Vascular were worth $4,759,000 as of its most []

LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced a quarterly dividend on Tuesday, October 26th, Zacks reports. Shareholders of record on Friday, November 19th will be given a dividend of 0.11 per share by the medical instruments supplier on Thursday, December 2nd. This represents a $0.44 annualized dividend and a yield of 0.82%. The ex-dividend date is Thursday, []

Wall Street brokerages expect LeMaitre Vascular, Inc. (NASDAQ:LMAT) to post earnings of $0.31 per share for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for LeMaitre Vasculars earnings. The highest EPS estimate is $0.32 and the lowest is $0.30. LeMaitre Vascular reported earnings per share of $0.34 during the same quarter last []

LeMaitre Vascular, Inc. (NASDAQ:LMAT) declared a quarterly dividend on Tuesday, October 26th, Zacks reports. Shareholders of record on Friday, November 19th will be paid a dividend of 0.11 per share by the medical instruments supplier on Thursday, December 2nd. This represents a $0.44 dividend on an annualized basis and a yield of 0.80%. The ex-dividend []